Multicenter prospective validation of the Baveno IV and Baveno II/III criteria in cirrhosis patients with variceal bleeding

The criteria for defining failure to control bleeding in cirrhosis patients were introduced at the Baveno II/III meetings and were widely used as endpoints in clinical trials. Because they lacked specificity, the Baveno IV criteria were proposed in 2005 and slightly modified in 2010 (Baveno V). Thes...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Hepatology (Baltimore, Md.) Md.), 2015-03, Vol.61 (3), p.1024-1032
Hauptverfasser: Thabut, Dominique, Rudler, Marika, Dib, Nina, Carbonell, Nicolas, Mathurin, Philippe, Saliba, Faouzi, Mallet, Alain, Massard, Julien, Bernard‐Chabert, Brigitte, Oberti, Frederic, Cales, Paul, Golmard, Jean‐Louis, Bureau, Christophe
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1032
container_issue 3
container_start_page 1024
container_title Hepatology (Baltimore, Md.)
container_volume 61
creator Thabut, Dominique
Rudler, Marika
Dib, Nina
Carbonell, Nicolas
Mathurin, Philippe
Saliba, Faouzi
Mallet, Alain
Massard, Julien
Bernard‐Chabert, Brigitte
Oberti, Frederic
Cales, Paul
Golmard, Jean‐Louis
Bureau, Christophe
description The criteria for defining failure to control bleeding in cirrhosis patients were introduced at the Baveno II/III meetings and were widely used as endpoints in clinical trials. Because they lacked specificity, the Baveno IV criteria were proposed in 2005 and slightly modified in 2010 (Baveno V). These criteria included a new index for patients undergoing transfusion, called adjusted‐blood‐requirement‐index (ABRI = number of blood units/(final‐initial hematocrit + 0.01)), with a cutoff value of 0.75. In this multicenter prospective study, we sought to 1) validate the Baveno IV/V criteria; 2) compare them to the Baveno II/III criteria; 3) assess ABRI performance using a standardized calculation. The key inclusion criteria were: 1) variceal bleeding; 2) cirrhosis; 3) no need to modify the transfusion policy. The patients were classified according to the Baveno IV, V, and II/III criteria. The gold standard for failure during a 5‐day period was the clinical judgment of three independent experts, blinded to the Baveno assessments. A total of 249 patients were included. The experts' agreement in clinical judgment of the failure was 80%. Failure occurred in 20.5% of patients; the c‐statistics were 0.72 versus 0.64 and 0.65 for Baveno IV versus Baveno II/III and Baveno V criteria (P = 0.001 for both). ABRI did not improve the diagnostic performance of the Baveno IV criteria. The Baveno IV, but not Baveno II/III, criteria independently predicted survival. Conclusion: The Baveno IV criteria demonstrated a higher accuracy than the Baveno II/III and Baveno V criteria for assessing failure to control bleeding and predicted survival independently. Together, our results show that ABRI is not a useful metric, and the Baveno IV criteria should replace the Baveno II/III criteria. (Hepatology 2015;61:1024–1032)
doi_str_mv 10.1002/hep.27407
format Article
fullrecord <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_01392302v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1658420681</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4207-4d3d73f4fdd072afdc1c3eb7dd8dabe7f6c5df0a6179c373f1715ae6e81873223</originalsourceid><addsrcrecordid>eNqNkU1P3DAQhq2qqGyhh_6BylIv7SGsP5LYOQICNtIiOECvlteeNEbeJLWTRah_Hi9Lt1KlSpwsW888npkXoc-UnFBC2LyF4YSJnIh3aEYLJjLOC_IezQgTJKsorw7RxxgfCCFVzuQHdMgKKipayhn6fT350RnoRgh4CH0cwIxuA3ijvbN6dH2H-waPLeAzvYGux_UPrDu7v9Xzuq6xCS4JnMauw8aF0PbRRTyk-mSO-NGNbTKG9JH2eOUBrOt-HqODRvsIn17PI3R_eXF3vsiWN1f1-ekyMzkjIsstt4I3eWMtEUw31lDDYSWslVavQDSlKWxDdJlmMjyRVNBCQwmSSsEZ40fo-87baq-G4NY6PKleO7U4XartG0krYpywDU3stx2bdvFrgjiqtYsGvNcd9FNUtCxTU5JVb0ELmdhSbtGv_6AP_RS6NPSWEryglZB_-zQphxig2TdLidoGrVLQ6iXoxH55NU6rNdg9-SfZBMx3wKPz8PR_k1pc3O6UzwgIsU8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1657351978</pqid></control><display><type>article</type><title>Multicenter prospective validation of the Baveno IV and Baveno II/III criteria in cirrhosis patients with variceal bleeding</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Thabut, Dominique ; Rudler, Marika ; Dib, Nina ; Carbonell, Nicolas ; Mathurin, Philippe ; Saliba, Faouzi ; Mallet, Alain ; Massard, Julien ; Bernard‐Chabert, Brigitte ; Oberti, Frederic ; Cales, Paul ; Golmard, Jean‐Louis ; Bureau, Christophe</creator><creatorcontrib>Thabut, Dominique ; Rudler, Marika ; Dib, Nina ; Carbonell, Nicolas ; Mathurin, Philippe ; Saliba, Faouzi ; Mallet, Alain ; Massard, Julien ; Bernard‐Chabert, Brigitte ; Oberti, Frederic ; Cales, Paul ; Golmard, Jean‐Louis ; Bureau, Christophe ; French Club for the Study of Portal Hypertension (CFEHTP) ; for the French Club for the Study of Portal Hypertension (CFEHTP)</creatorcontrib><description>The criteria for defining failure to control bleeding in cirrhosis patients were introduced at the Baveno II/III meetings and were widely used as endpoints in clinical trials. Because they lacked specificity, the Baveno IV criteria were proposed in 2005 and slightly modified in 2010 (Baveno V). These criteria included a new index for patients undergoing transfusion, called adjusted‐blood‐requirement‐index (ABRI = number of blood units/(final‐initial hematocrit + 0.01)), with a cutoff value of 0.75. In this multicenter prospective study, we sought to 1) validate the Baveno IV/V criteria; 2) compare them to the Baveno II/III criteria; 3) assess ABRI performance using a standardized calculation. The key inclusion criteria were: 1) variceal bleeding; 2) cirrhosis; 3) no need to modify the transfusion policy. The patients were classified according to the Baveno IV, V, and II/III criteria. The gold standard for failure during a 5‐day period was the clinical judgment of three independent experts, blinded to the Baveno assessments. A total of 249 patients were included. The experts' agreement in clinical judgment of the failure was 80%. Failure occurred in 20.5% of patients; the c‐statistics were 0.72 versus 0.64 and 0.65 for Baveno IV versus Baveno II/III and Baveno V criteria (P = 0.001 for both). ABRI did not improve the diagnostic performance of the Baveno IV criteria. The Baveno IV, but not Baveno II/III, criteria independently predicted survival. Conclusion: The Baveno IV criteria demonstrated a higher accuracy than the Baveno II/III and Baveno V criteria for assessing failure to control bleeding and predicted survival independently. Together, our results show that ABRI is not a useful metric, and the Baveno IV criteria should replace the Baveno II/III criteria. (Hepatology 2015;61:1024–1032)</description><identifier>ISSN: 0270-9139</identifier><identifier>EISSN: 1527-3350</identifier><identifier>DOI: 10.1002/hep.27407</identifier><identifier>PMID: 25179168</identifier><identifier>CODEN: HPTLD9</identifier><language>eng</language><publisher>United States: Wolters Kluwer Health, Inc</publisher><subject>Blood Transfusion ; Esophageal and Gastric Varices - diagnosis ; Esophageal and Gastric Varices - mortality ; Esophageal and Gastric Varices - therapy ; Gastrointestinal Hemorrhage - diagnosis ; Gastrointestinal Hemorrhage - mortality ; Gastrointestinal Hemorrhage - therapy ; Hepatology ; Humans ; Life Sciences ; Liver Cirrhosis - complications ; Prospective Studies ; Treatment Failure</subject><ispartof>Hepatology (Baltimore, Md.), 2015-03, Vol.61 (3), p.1024-1032</ispartof><rights>2014 by the American Association for the Study of Liver Diseases</rights><rights>2014 by the American Association for the Study of Liver Diseases.</rights><rights>2015 by the American Association for the Study of Liver Diseases</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4207-4d3d73f4fdd072afdc1c3eb7dd8dabe7f6c5df0a6179c373f1715ae6e81873223</citedby><cites>FETCH-LOGICAL-c4207-4d3d73f4fdd072afdc1c3eb7dd8dabe7f6c5df0a6179c373f1715ae6e81873223</cites><orcidid>0000-0003-3447-2025 ; 0000-0003-4866-5274</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhep.27407$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhep.27407$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25179168$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-01392302$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Thabut, Dominique</creatorcontrib><creatorcontrib>Rudler, Marika</creatorcontrib><creatorcontrib>Dib, Nina</creatorcontrib><creatorcontrib>Carbonell, Nicolas</creatorcontrib><creatorcontrib>Mathurin, Philippe</creatorcontrib><creatorcontrib>Saliba, Faouzi</creatorcontrib><creatorcontrib>Mallet, Alain</creatorcontrib><creatorcontrib>Massard, Julien</creatorcontrib><creatorcontrib>Bernard‐Chabert, Brigitte</creatorcontrib><creatorcontrib>Oberti, Frederic</creatorcontrib><creatorcontrib>Cales, Paul</creatorcontrib><creatorcontrib>Golmard, Jean‐Louis</creatorcontrib><creatorcontrib>Bureau, Christophe</creatorcontrib><creatorcontrib>French Club for the Study of Portal Hypertension (CFEHTP)</creatorcontrib><creatorcontrib>for the French Club for the Study of Portal Hypertension (CFEHTP)</creatorcontrib><title>Multicenter prospective validation of the Baveno IV and Baveno II/III criteria in cirrhosis patients with variceal bleeding</title><title>Hepatology (Baltimore, Md.)</title><addtitle>Hepatology</addtitle><description>The criteria for defining failure to control bleeding in cirrhosis patients were introduced at the Baveno II/III meetings and were widely used as endpoints in clinical trials. Because they lacked specificity, the Baveno IV criteria were proposed in 2005 and slightly modified in 2010 (Baveno V). These criteria included a new index for patients undergoing transfusion, called adjusted‐blood‐requirement‐index (ABRI = number of blood units/(final‐initial hematocrit + 0.01)), with a cutoff value of 0.75. In this multicenter prospective study, we sought to 1) validate the Baveno IV/V criteria; 2) compare them to the Baveno II/III criteria; 3) assess ABRI performance using a standardized calculation. The key inclusion criteria were: 1) variceal bleeding; 2) cirrhosis; 3) no need to modify the transfusion policy. The patients were classified according to the Baveno IV, V, and II/III criteria. The gold standard for failure during a 5‐day period was the clinical judgment of three independent experts, blinded to the Baveno assessments. A total of 249 patients were included. The experts' agreement in clinical judgment of the failure was 80%. Failure occurred in 20.5% of patients; the c‐statistics were 0.72 versus 0.64 and 0.65 for Baveno IV versus Baveno II/III and Baveno V criteria (P = 0.001 for both). ABRI did not improve the diagnostic performance of the Baveno IV criteria. The Baveno IV, but not Baveno II/III, criteria independently predicted survival. Conclusion: The Baveno IV criteria demonstrated a higher accuracy than the Baveno II/III and Baveno V criteria for assessing failure to control bleeding and predicted survival independently. Together, our results show that ABRI is not a useful metric, and the Baveno IV criteria should replace the Baveno II/III criteria. (Hepatology 2015;61:1024–1032)</description><subject>Blood Transfusion</subject><subject>Esophageal and Gastric Varices - diagnosis</subject><subject>Esophageal and Gastric Varices - mortality</subject><subject>Esophageal and Gastric Varices - therapy</subject><subject>Gastrointestinal Hemorrhage - diagnosis</subject><subject>Gastrointestinal Hemorrhage - mortality</subject><subject>Gastrointestinal Hemorrhage - therapy</subject><subject>Hepatology</subject><subject>Humans</subject><subject>Life Sciences</subject><subject>Liver Cirrhosis - complications</subject><subject>Prospective Studies</subject><subject>Treatment Failure</subject><issn>0270-9139</issn><issn>1527-3350</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkU1P3DAQhq2qqGyhh_6BylIv7SGsP5LYOQICNtIiOECvlteeNEbeJLWTRah_Hi9Lt1KlSpwsW888npkXoc-UnFBC2LyF4YSJnIh3aEYLJjLOC_IezQgTJKsorw7RxxgfCCFVzuQHdMgKKipayhn6fT350RnoRgh4CH0cwIxuA3ijvbN6dH2H-waPLeAzvYGux_UPrDu7v9Xzuq6xCS4JnMauw8aF0PbRRTyk-mSO-NGNbTKG9JH2eOUBrOt-HqODRvsIn17PI3R_eXF3vsiWN1f1-ekyMzkjIsstt4I3eWMtEUw31lDDYSWslVavQDSlKWxDdJlmMjyRVNBCQwmSSsEZ40fo-87baq-G4NY6PKleO7U4XartG0krYpywDU3stx2bdvFrgjiqtYsGvNcd9FNUtCxTU5JVb0ELmdhSbtGv_6AP_RS6NPSWEryglZB_-zQphxig2TdLidoGrVLQ6iXoxH55NU6rNdg9-SfZBMx3wKPz8PR_k1pc3O6UzwgIsU8</recordid><startdate>201503</startdate><enddate>201503</enddate><creator>Thabut, Dominique</creator><creator>Rudler, Marika</creator><creator>Dib, Nina</creator><creator>Carbonell, Nicolas</creator><creator>Mathurin, Philippe</creator><creator>Saliba, Faouzi</creator><creator>Mallet, Alain</creator><creator>Massard, Julien</creator><creator>Bernard‐Chabert, Brigitte</creator><creator>Oberti, Frederic</creator><creator>Cales, Paul</creator><creator>Golmard, Jean‐Louis</creator><creator>Bureau, Christophe</creator><general>Wolters Kluwer Health, Inc</general><general>Wiley-Blackwell</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0003-3447-2025</orcidid><orcidid>https://orcid.org/0000-0003-4866-5274</orcidid></search><sort><creationdate>201503</creationdate><title>Multicenter prospective validation of the Baveno IV and Baveno II/III criteria in cirrhosis patients with variceal bleeding</title><author>Thabut, Dominique ; Rudler, Marika ; Dib, Nina ; Carbonell, Nicolas ; Mathurin, Philippe ; Saliba, Faouzi ; Mallet, Alain ; Massard, Julien ; Bernard‐Chabert, Brigitte ; Oberti, Frederic ; Cales, Paul ; Golmard, Jean‐Louis ; Bureau, Christophe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4207-4d3d73f4fdd072afdc1c3eb7dd8dabe7f6c5df0a6179c373f1715ae6e81873223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Blood Transfusion</topic><topic>Esophageal and Gastric Varices - diagnosis</topic><topic>Esophageal and Gastric Varices - mortality</topic><topic>Esophageal and Gastric Varices - therapy</topic><topic>Gastrointestinal Hemorrhage - diagnosis</topic><topic>Gastrointestinal Hemorrhage - mortality</topic><topic>Gastrointestinal Hemorrhage - therapy</topic><topic>Hepatology</topic><topic>Humans</topic><topic>Life Sciences</topic><topic>Liver Cirrhosis - complications</topic><topic>Prospective Studies</topic><topic>Treatment Failure</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Thabut, Dominique</creatorcontrib><creatorcontrib>Rudler, Marika</creatorcontrib><creatorcontrib>Dib, Nina</creatorcontrib><creatorcontrib>Carbonell, Nicolas</creatorcontrib><creatorcontrib>Mathurin, Philippe</creatorcontrib><creatorcontrib>Saliba, Faouzi</creatorcontrib><creatorcontrib>Mallet, Alain</creatorcontrib><creatorcontrib>Massard, Julien</creatorcontrib><creatorcontrib>Bernard‐Chabert, Brigitte</creatorcontrib><creatorcontrib>Oberti, Frederic</creatorcontrib><creatorcontrib>Cales, Paul</creatorcontrib><creatorcontrib>Golmard, Jean‐Louis</creatorcontrib><creatorcontrib>Bureau, Christophe</creatorcontrib><creatorcontrib>French Club for the Study of Portal Hypertension (CFEHTP)</creatorcontrib><creatorcontrib>for the French Club for the Study of Portal Hypertension (CFEHTP)</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Hepatology (Baltimore, Md.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Thabut, Dominique</au><au>Rudler, Marika</au><au>Dib, Nina</au><au>Carbonell, Nicolas</au><au>Mathurin, Philippe</au><au>Saliba, Faouzi</au><au>Mallet, Alain</au><au>Massard, Julien</au><au>Bernard‐Chabert, Brigitte</au><au>Oberti, Frederic</au><au>Cales, Paul</au><au>Golmard, Jean‐Louis</au><au>Bureau, Christophe</au><aucorp>French Club for the Study of Portal Hypertension (CFEHTP)</aucorp><aucorp>for the French Club for the Study of Portal Hypertension (CFEHTP)</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Multicenter prospective validation of the Baveno IV and Baveno II/III criteria in cirrhosis patients with variceal bleeding</atitle><jtitle>Hepatology (Baltimore, Md.)</jtitle><addtitle>Hepatology</addtitle><date>2015-03</date><risdate>2015</risdate><volume>61</volume><issue>3</issue><spage>1024</spage><epage>1032</epage><pages>1024-1032</pages><issn>0270-9139</issn><eissn>1527-3350</eissn><coden>HPTLD9</coden><abstract>The criteria for defining failure to control bleeding in cirrhosis patients were introduced at the Baveno II/III meetings and were widely used as endpoints in clinical trials. Because they lacked specificity, the Baveno IV criteria were proposed in 2005 and slightly modified in 2010 (Baveno V). These criteria included a new index for patients undergoing transfusion, called adjusted‐blood‐requirement‐index (ABRI = number of blood units/(final‐initial hematocrit + 0.01)), with a cutoff value of 0.75. In this multicenter prospective study, we sought to 1) validate the Baveno IV/V criteria; 2) compare them to the Baveno II/III criteria; 3) assess ABRI performance using a standardized calculation. The key inclusion criteria were: 1) variceal bleeding; 2) cirrhosis; 3) no need to modify the transfusion policy. The patients were classified according to the Baveno IV, V, and II/III criteria. The gold standard for failure during a 5‐day period was the clinical judgment of three independent experts, blinded to the Baveno assessments. A total of 249 patients were included. The experts' agreement in clinical judgment of the failure was 80%. Failure occurred in 20.5% of patients; the c‐statistics were 0.72 versus 0.64 and 0.65 for Baveno IV versus Baveno II/III and Baveno V criteria (P = 0.001 for both). ABRI did not improve the diagnostic performance of the Baveno IV criteria. The Baveno IV, but not Baveno II/III, criteria independently predicted survival. Conclusion: The Baveno IV criteria demonstrated a higher accuracy than the Baveno II/III and Baveno V criteria for assessing failure to control bleeding and predicted survival independently. Together, our results show that ABRI is not a useful metric, and the Baveno IV criteria should replace the Baveno II/III criteria. (Hepatology 2015;61:1024–1032)</abstract><cop>United States</cop><pub>Wolters Kluwer Health, Inc</pub><pmid>25179168</pmid><doi>10.1002/hep.27407</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-3447-2025</orcidid><orcidid>https://orcid.org/0000-0003-4866-5274</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0270-9139
ispartof Hepatology (Baltimore, Md.), 2015-03, Vol.61 (3), p.1024-1032
issn 0270-9139
1527-3350
language eng
recordid cdi_hal_primary_oai_HAL_hal_01392302v1
source MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Blood Transfusion
Esophageal and Gastric Varices - diagnosis
Esophageal and Gastric Varices - mortality
Esophageal and Gastric Varices - therapy
Gastrointestinal Hemorrhage - diagnosis
Gastrointestinal Hemorrhage - mortality
Gastrointestinal Hemorrhage - therapy
Hepatology
Humans
Life Sciences
Liver Cirrhosis - complications
Prospective Studies
Treatment Failure
title Multicenter prospective validation of the Baveno IV and Baveno II/III criteria in cirrhosis patients with variceal bleeding
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T01%3A58%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Multicenter%20prospective%20validation%20of%20the%20Baveno%20IV%20and%20Baveno%20II/III%20criteria%20in%20cirrhosis%20patients%20with%20variceal%20bleeding&rft.jtitle=Hepatology%20(Baltimore,%20Md.)&rft.au=Thabut,%20Dominique&rft.aucorp=French%20Club%20for%20the%20Study%20of%20Portal%20Hypertension%20(CFEHTP)&rft.date=2015-03&rft.volume=61&rft.issue=3&rft.spage=1024&rft.epage=1032&rft.pages=1024-1032&rft.issn=0270-9139&rft.eissn=1527-3350&rft.coden=HPTLD9&rft_id=info:doi/10.1002/hep.27407&rft_dat=%3Cproquest_hal_p%3E1658420681%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1657351978&rft_id=info:pmid/25179168&rfr_iscdi=true